Avenue Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Avenue Therapeutics

10/08/2023 23:32

* Avenue Therapeutics Inc  ATXI.OQ  reported a quarterly
adjusted
loss of 52 cents​​ per share for the quarter ended in June. The
lone analyst forecast for the quarter was for a loss of 29 cents
per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Avenue Therapeutics Inc's reported EPS for the quarter was
a
loss of 52 cents​.
    * The mean earnings estimate of analysts had fallen by
about 93.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Avenue Therapeutics Inc shares had fallen by 12.0% this
quarter and lost 11.2% so far this year.
    * The company reported a quarterly loss of $4.01 million.
    * Wall Street's median 12-month price target for Avenue
Therapeutics Inc is $32.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 10:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.29          -0.52          Missed
 Mar. 31 2023      -0.13          -1.35          Missed
 Dec. 31 2022      -0.15